{"id":1385,"date":"2025-02-15T20:24:33","date_gmt":"2025-02-15T20:24:33","guid":{"rendered":"https:\/\/naujienosversle.lt\/index.php\/2025\/02\/15\/biotech-startup-verigraft-uzsitikrina-12-mln\/"},"modified":"2025-02-15T20:24:33","modified_gmt":"2025-02-15T20:24:33","slug":"biotech-startup-verigraft-uzsitikrina-12-mln","status":"publish","type":"post","link":"https:\/\/naujienosversle.lt\/index.php\/2025\/02\/15\/biotech-startup-verigraft-uzsitikrina-12-mln\/","title":{"rendered":"\u201eBiotech Startup Verigraft\u201c u\u017esitikrina 1,2 mln"},"content":{"rendered":"<p> <br \/>\n<\/p>\n<div>\n<p data-start=\"106\" data-end=\"703\">Geteborge \u012fsik\u016brusi biotechnologij\u0173 \u012fmon\u0117 <strong>Verigraftas<\/strong> Buvo suteikta 1,2 mln.<\/p>\n<p data-start=\"106\" data-end=\"703\">\u0160ia iniciatyva siekiama i\u0161spr\u0119sti reik\u0161mingus dabartin\u0117s transplantato technologijos i\u0161\u0161\u016bkius, \u012fskaitant ribot\u0105 \u017emoni\u0173 tonizuot\u0173 med\u017eiag\u0173 prieinamum\u0105, prast\u0105 integracij\u0105 ir auk\u0161t\u0105 gedim\u0173 procent\u0105. Projekto s\u0117km\u0117 gal\u0117t\u0173 paruo\u0161ti keli\u0105 pradiniams klinikiniams tyrimams su \u017emon\u0117mis ir ateityje komercializavimui, o potencialus pritaikymas vir\u0161ija kraujagysli\u0173 transplantatas.<\/p>\n<p data-start=\"106\" data-end=\"703\">\u201c<em>\u0160i \u201eEurostars\u201c dotacija yra pagrindinis \u201eVerigraft\u201c ir \u201eRegenerative Medicine\u201c etapas. Su \u201ePrepper\u201c mes spart\u0117jame suasmenint\u0173 audini\u0173 terapij\u0173 ateit\u012f<\/em>&#8211; sak\u0117 <strong>Dr Raimund Strehl<\/strong>Verigraft CTO. \u201c<em>Prognozuojama<\/em>\u201c.<\/p>\n<p data-start=\"106\" data-end=\"703\">2004 m. \u012ek\u016br\u0117 Janas Holgerssonas, \u201eVerigraft\u201c yra biotechnologij\u0173 kompanija, pagr\u012fsta Karolinska institute, ji i\u0161augo \u012f pramonini\u0173 audini\u0173 in\u017einerijos ir pa\u017eengusios regeneracin\u0117s medicinos pirmtak\u0105.<\/p>\n<p data-start=\"106\" data-end=\"703\">Bendrov\u0117 turi sutelkt\u0105 individualizuot\u0173 audini\u0173 tyrim\u0173 ir pl\u0117tros vamzdyn\u0105, nukreipt\u0105 \u012f tokias sritis kaip \u0161irdies ir kraujagysli\u0173 bei neuron\u0173 ligos. \u201eVerigraft\u201c komercializuos suasmenint\u0173 audini\u0173 sukurt\u0173 transplantat\u0173 serij\u0105 pasaulin\u0117je rinkoje.<\/p>\n<p>\u201c<em>\u201eVerigraft\u201c si\u016blo unikali\u0105, prover\u017eio technologij\u0105 pa\u017eengusios regeneracin\u0117s medicinos srityje. \u0160i technologija suteikia galimyb\u0119 individualizuoti audinius ir organus. Tai gal\u0117s sukelti transplantacijos medicinos paradigmos poslink\u012f<\/em>&#8211; sak\u0117 <strong>Petter Bj\u00f6rquist<\/strong> PhD, generalinis direktorius.<\/p>\n<p data-start=\"705\" data-end=\"1106\">Vykdomame tyrime \u201eVerigraft\u201c s\u0117kmingai persodino j\u0173 suasmenint\u0105 audini\u0173 in\u017einerijos ven\u0105 P-TEV \u2122, \u012f pacientus, ken\u010dian\u010dius nuo l\u0117tinio veninio nepakankamumo (CVI)-b\u016bkl\u0117s, daran\u010dios \u012ftak\u0105 giliai veninei sistemai, d\u0117l kurios skausmingi apatini\u0173 koj\u0173 patinimas ir opos yra skausmingi ir opos. . Pa\u017eym\u0117tina, kad vienas pacientas Ispanijoje dabar pirm\u0105 kart\u0105 per metus gali vaik\u0161\u010dioti be pagalbos ir dalyvauti futbolo var\u017eybose.<\/p>\n<p data-start=\"1349\" data-end=\"1761\">Bendradarbiaudamas su \u201eSally3D SA\u201c (\u0160veicarija), \u201eRise\u201c (\u0160vedija) ir Sahlgrenskos universitetine ligonine (\u0160vedija), \u201eVerigraft\u201c integruos patobulint\u0105 3D spausdinim\u0105, tirpalo p\u016bsto pluo\u0161to technologij\u0105 ir individualizuot\u0105 audini\u0173 in\u017einerij\u0105. Tikslas yra sukurti pritaikytus kraujagysli\u0173 transplantatas, imituojan\u010dias nat\u016bralias arterijas, si\u016blan\u010dias puik\u0173 patvarum\u0105 ir skland\u0173 integracij\u0105, palyginti su dabartin\u0117mis sintetin\u0117mis alternatyvomis.<\/p>\n<p data-start=\"1763\" data-end=\"2007\">Projektas \u201ePrepper\u201c gavo finansavim\u0105 i\u0161 \u201eEurostars-3\u201c bendrosios programos, kartu su Europos S\u0105jungos \u201eHorizon Europe\u201c tyrim\u0173 ir inovacij\u0173 programos finansavimu. \u201eEurostars\u201c yra Europos partneryst\u0117s novatori\u0161k\u0173 MV\u012e dalis.<\/p>\n<p data-start=\"2009\" data-end=\"2265\">Pasinaudodamas \u0161ia dotacija ir bendradarbiavimo patirtimi, \u201eVerigraft\u201c siekia pakeisti revoliucij\u0105 regeneracin\u0117s medicinos srityje, teikdamas novatori\u0161kus sprendimus pacientams, kuriems reikalingi arteriniai transplantatai, ir i\u0161d\u0117styti Europ\u0105 kaip 3D biologin\u0117s technologijos lyder\u0119.<\/p>\n<\/div>\n<p><script>\n        !function(f,b,e,v,n,t,s)\n        {if(f.fbq)return;n=f.fbq=function(){n.callMethod?\n            n.callMethod.apply(n,arguments):n.queue.push(arguments)};\n            if(!f._fbq)f._fbq=n;n.push=n;n.loaded=!0;n.version='2.0';\n            n.queue=();t=b.createElement(e);t.async=!0;\n            t.src=v;s=b.getElementsByTagName(e)(0);\n            s.parentNode.insertBefore(t,s)}(window, document,'script',\n            'https:\/\/connect.facebook.net\/en_US\/fbevents.js');\n        fbq('init', '154586475232058');\n        fbq('track', 'PageView');\n    <\/script><br \/>\n<br \/><br \/>\n<br \/><a href=\"https:\/\/www.eu-startups.com\/2025\/02\/biotech-startup-verigraft-secures-e1-2-million-to-advance-3d-printed-arterial-grafts\/\">Source link <\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Geteborge \u012fsik\u016brusi biotechnologij\u0173 \u012fmon\u0117 Verigraftas Buvo suteikta 1,2 mln. \u0160ia iniciatyva siekiama i\u0161spr\u0119sti reik\u0161mingus dabartin\u0117s transplantato technologijos i\u0161\u0161\u016bkius, \u012fskaitant ribot\u0105 \u017emoni\u0173 tonizuot\u0173 med\u017eiag\u0173 prieinamum\u0105, prast\u0105 integracij\u0105 ir auk\u0161t\u0105 gedim\u0173 procent\u0105. Projekto s\u0117km\u0117 gal\u0117t\u0173 paruo\u0161ti keli\u0105 pradiniams klinikiniams tyrimams su \u017emon\u0117mis ir ateityje komercializavimui, o potencialus pritaikymas vir\u0161ija kraujagysli\u0173 transplantatas. \u201c\u0160i \u201eEurostars\u201c dotacija yra pagrindinis \u201eVerigraft\u201c&#8230;<\/p>\n","protected":false},"author":1,"featured_media":1386,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"categories":[6],"tags":[3014,56,2893,55,3015],"class_list":["post-1385","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europos-verslo-naujienos","tag-biotech","tag-mln","tag-startup","tag-uzsitikrina","tag-verigraft"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/posts\/1385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/comments?post=1385"}],"version-history":[{"count":0,"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/posts\/1385\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/media\/1386"}],"wp:attachment":[{"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/media?parent=1385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/categories?post=1385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/naujienosversle.lt\/index.php\/wp-json\/wp\/v2\/tags?post=1385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}